Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K103531
    Date Cleared
    2011-12-01

    (365 days)

    Product Code
    Regulation Number
    862.1345
    Reference & Predicate Devices
    Why did this record match?
    Device Name :

    PRESTIGE 24I; BIOLIS 24I; MGC 240

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Biolis 24i Clinical Chemistry Analyzer is a discrete photometric clinical chemistry analyzer. The device is intended to duplicate manual analytical procedures by automating various steps such as pipetting, heating, measuring color intensity, and reporting results. The device is intended to be used with certain materials to measure various analytes of diagnostic interest including glucose.

    The Biolis 24i analyzer with glucose hexokinase assay is intended to measure glucose quantitatively in human serum. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic glycemia, and of the pancreatic islet cell carcinoma.

    Device Description

    Using photometry, the Biolis 24i instrument measures the glucose concentration in serum by monitoring the change in absorbance at 340 nm. Additionally, the Biolis 24i with Ion-Selective Elective module additionally measures the concentration of the electrolytes, sodium, potassium and chloride in serum, using indirect potentiometry.

    AI/ML Overview

    Here's an analysis of the provided text regarding the acceptance criteria and study for the Tokyo Boeki Medisys Inc. Biolis 24i Clinical Chemistry Analyzer, specifically for glucose measurement:


    Acceptance Criteria and Device Performance for Biolis 24i Clinical Chemistry Analyzer (Glucose)

    1. Table of Acceptance Criteria and Reported Device Performance

    The provided 510(k) summary does not explicitly state pre-defined acceptance criteria values for each performance characteristic. Instead, it presents the results of the performance studies and implicitly suggests that these results demonstrated substantial equivalence to the predicate device. For the purpose of this response, I infer the reported performance as the outcome that met the (unspecified) acceptance criteria for substantial equivalence.

    Performance CharacteristicAcceptance Criteria (Inferred)Reported Device Performance (Biolis 24i)
    Method Comparison (vs. Predicate SYNCHRON CX 7)Correlation Coefficient (R) close to 1GLU: 0.999
    Slope (Least-Squares) close to 1GLU: 0.974
    Y-axis intercept close to 0GLU: 2.22
    Precision (Repeatability)Low Coefficient of Variation (CV%)Serum 1: 1.3%
    Serum 2: 1.3%
    Serum 3: 1.2%
    Serum 4: 1.1%
    Serum 5: 1.5%
    Precision (Total Imprecision)Low Coefficient of Variation (CV%)Analyzer 2229450610:
    Control 1: 2.4%
    Serum Pool 1: 2.5%
    Serum Pool 2: 2.1%
    Control 2: 2.3%
    Analyzer 2227671109:
    Control 1: 1.9%
    Serum Pool 1: 2.3%
    Serum Pool 2: 1.9%
    Control 2: 2.2%
    LinearityCorrelation close to 10.9982
    Slope close to 10.948
    Intercept close to 02.45
    Range of linearity25 - 500 mg/dL
    SensitivityLow values for LoB, LoD, LoQLoB: 3.64 mg/dL
    LoD: 5.64 mg/dL
    LoQ: 10 mg/dL
    Interferences
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1